About Juvena Therapeutics
Juvena Therapeutics develops biologic drug candidates by identifying and engineering human stem cell-secreted proteins into therapies that aim to restore tissue homeostasis and improve muscle and metabolic function. It uses a proprietary, AI-enabled discovery platform that maps the therapeutic potential of the secretome to disease phenotypes and advances selected proteins into engineered biologic medicines. The company’s pipeline includes engineered proteins for muscle regeneration and metabolic indications, with its lead candidate being evaluated in clinical studies for muscle-related disease. Juvena collaborates with partners to expand discovery efforts and explore new therapeutic targets using its computational and biological capabilities.
Open positions (1)
Company details
Funding
Total raised
$86.3M
Last stage
Series B
Investors
Founders
Jeremy O'Connell
Chief Scientific Officer overseeing research strategy, pre-clinical science, manufacturing, and IP. PhD from UT Austin, postdoctoral fellowship at Harvard Medical School (Steven Gygi lab). Expertise in proteomics, systems biology, and machine learning.
LinkedIn
Hanadie Yousef
Scientist-turned-entrepreneur and global thought leader in AI-driven regenerative medicine. PhD from UC Berkeley (Molecular & Cell Biology), postdoctoral fellow at Stanford. Co-founded Juvena in 2017; served as CEO, CFO, and Board Chair through 2025.
LinkedInWhat happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.